248 related articles for article (PubMed ID: 32109849)
1. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group.
Pasqualini C; Furtwängler R; van Tinteren H; Teixeira RAP; Acha T; Howell L; Vujanic G; Godzinski J; Melchior P; Smets AM; Coulomb-L'Hermine A; Brisse H; Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Graf N; Verschuur AC
Eur J Cancer; 2020 Mar; 128():38-46. PubMed ID: 32109849
[TBL] [Abstract][Full Text] [Related]
2. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG).
van den Heuvel-Eibrink MM; van Tinteren H; Bergeron C; Coulomb-L'Hermine A; de Camargo B; Leuschner I; Sandstedt B; Acha T; Godzinski J; Oldenburger F; Gooskens SL; de Kraker J; Vujanic GM; Pritchard-Jones K; Graf N
Eur J Cancer; 2015 Mar; 51(4):498-506. PubMed ID: 25592561
[TBL] [Abstract][Full Text] [Related]
3. Response to letter commenting on "Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)".
; van den Heuvel-Eibrink MM; Pritchard-Jones K; van Tinteren H; Graf N
Eur J Cancer; 2015 May; 51(8):995-6. PubMed ID: 25840668
[No Abstract] [Full Text] [Related]
4. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG.
Fajardo RD; van den Heuvel-Eibrink MM; van Tinteren H; Spreafico F; Acha T; Bergeron C; de Camargo B; Oldenburger F; Rübe C; Oue T; Vokuhl C; de Krijger RR; Vujanic G; Sebire N; Coulomb-L'Hermine A; Collini P; Gandola L; Pritchard-Jones K; Graf N; Janssens GO; van Grotel M
Pediatr Blood Cancer; 2020 Feb; 67(2):e28039. PubMed ID: 31625685
[TBL] [Abstract][Full Text] [Related]
5. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.
Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Acha T; Godzinski J; Oldenburger F; Boccon-Gibod L; Leuschner I; Vujanic G; Sandstedt B; de Kraker J; van Tinteren H; Graf N;
Lancet; 2015 Sep; 386(9999):1156-64. PubMed ID: 26164096
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies.
Mifsud W; Furtwängler R; Vokuhl C; D'Hooghe E; Pritchard-Jones K; Graf N; Vujanić GM
Eur J Cancer; 2022 May; 166():1-7. PubMed ID: 35255331
[TBL] [Abstract][Full Text] [Related]
7. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
Weirich A; Ludwig R; Graf N; Abel U; Leuschner I; Vujanic GM; Mehls O; Boos J; Beck J; Royer-Pokora B; Voûte PA
Ann Oncol; 2004 May; 15(5):808-20. PubMed ID: 15111352
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy - the United Kingdom experience.
Irtan S; Jitlal M; Bate J; Powis M; Vujanic G; Kelsey A; Walker J; Mitchell C; Machin D; Pritchard-Jones K;
Eur J Cancer; 2015 Jan; 51(2):225-32. PubMed ID: 25465191
[TBL] [Abstract][Full Text] [Related]
9. Update on relapses in unilateral nephroblastoma registered in 3 consecutive SIOP/GPOH studies - a report from the GPOH-nephroblastoma study group.
Furtwängler R; Nourkami N; Alkassar M; von Schweinitz D; Schenk JP; Rübe C; Siemer S; Leuschner I; Graf N
Klin Padiatr; 2011 May; 223(3):113-9. PubMed ID: 21509706
[TBL] [Abstract][Full Text] [Related]
10. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG).
Mavinkurve-Groothuis AM; van den Heuvel-Eibrink MM; Tytgat GA; van Tinteren H; Vujanic G; Pritchard-Jones KL; Howell L; Graf N; Bergeron C; Acha T; Catania S; Spreafico F
Pediatr Blood Cancer; 2015 Apr; 62(4):598-602. PubMed ID: 25546733
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry.
Dávila Fajardo R; Oldenburger E; Rübe C; López-Yurda M; Pritchard-Jones K; Bergeron C; Graf N; van Grotel M; van Tinteren H; Saunders D; van den Heuvel-Eibrink MM; Janssens GO; Oldenburger F
Pediatr Blood Cancer; 2018 Aug; 65(8):e27085. PubMed ID: 29693799
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH.
Weirich A; Leuschner I; Harms D; Vujanic GM; Tröger J; Abel U; Graf N; Schmidt D; Ludwig R; Voûte PA
Ann Oncol; 2001 Mar; 12(3):311-9. PubMed ID: 11332141
[TBL] [Abstract][Full Text] [Related]
14. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial.
de Kraker J; Graf N; van Tinteren H; Pein F; Sandstedt B; Godzinski J; Tournade MF;
Lancet; 2004 Oct 2-8; 364(9441):1229-35. PubMed ID: 15464183
[TBL] [Abstract][Full Text] [Related]
15. Nephron sparing surgery (NSS) for unilateral wilms tumor (UWT): the SIOP 2001 experience.
Wilde JC; Aronson DC; Sznajder B; Van Tinteren H; Powis M; Okoye B; Cecchetto G; Audry G; Fuchs J; Schweinitz DV; Heij H; Graf N; Bergeron C; Pritchard-Jones K; Van Den Heuvel-Eibrink M; Carli M; Oldenburger F; Sandstedt B; De Kraker J; Godzinski J
Pediatr Blood Cancer; 2014 Dec; 61(12):2175-9. PubMed ID: 25156758
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01.
Graf N; van Tinteren H; Bergeron C; Pein F; van den Heuvel-Eibrink MM; Sandstedt B; Schenk JP; Godzinski J; Oldenburger F; Furtwängler R; de Kraker J
Eur J Cancer; 2012 Nov; 48(17):3240-8. PubMed ID: 22795263
[TBL] [Abstract][Full Text] [Related]
17. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Beckwith JB; Breslow NE; Faria P; Moksness J; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S
J Clin Oncol; 1994 Oct; 12(10):2126-31. PubMed ID: 7931483
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of children with Wilms tumor treated on a SIOP WT 2001 protocol in a tertiary care hospital in south India.
John R; Kurian JJ; Sen S; Gupta MK; Jehangir S; Mathew LG; Mathai J
J Pediatr Urol; 2018 Dec; 14(6):547.e1-547.e7. PubMed ID: 30017606
[TBL] [Abstract][Full Text] [Related]
19. [Wilms' tumour of unfavorable histology--results of treatment with the SIOP 93-01 protocol at the Gdańsk centre. Preliminary report].
Stefanowicz J; Sierota D; Balcerska A; Stoba C
Med Wieku Rozwoj; 2004; 8(2 Pt 1):197-200. PubMed ID: 15738594
[TBL] [Abstract][Full Text] [Related]
20. Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.
Daw NC; Chi YY; Kim Y; Mullen EA; Kalapurakal JA; Tian J; Khanna G; Geller JI; Perlman EJ; Ehrlich PF; Warwick AB; Grundy PE; Fernandez CV; Dome JS;
Eur J Cancer; 2019 Sep; 118():58-66. PubMed ID: 31325873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
